Yongxin Han

CT-721, a Potent Bcr-Abl Inhibitor, Exhibits Excellent In Vitro and In Vivo Efficacy in the Treatment of Chronic Myeloid Leukemia

Ying Sun, De-guang Sun, Huan Wang, 2017, Journal of Cancer.

CT-707, a Novel FAK Inhibitor, Synergizes with Cabozantinib to Suppress Hepatocellular Carcinoma by Blocking Cabozantinib-Induced FAK Activation

Qiaojun He, Bo Yang, Ji Cao, 2016, Molecular Cancer Therapeutics.

Protein tyrosine phosphatase 1B deficiency or inhibition delays ErbB2-induced mammary tumorigenesis and protects from lung metastasis

B. Kennedy, W. Muller, M. Tremblay, 2007, Nature Genetics.